nodes	percent_of_prediction	percent_of_DWPC	metapath
Bismuth Subsalicylate—PTGS2—Etoposide—sarcoma	0.209	0.542	CbGbCtD
Bismuth Subsalicylate—PTGS1—Etoposide—sarcoma	0.176	0.458	CbGbCtD
Bismuth Subsalicylate—PTGS2—periosteum—sarcoma	0.0151	0.0722	CbGeAlD
Bismuth Subsalicylate—PTGS2—leg—sarcoma	0.012	0.0576	CbGeAlD
Bismuth Subsalicylate—TF—embryo—sarcoma	0.0108	0.0517	CbGeAlD
Bismuth Subsalicylate—PTGS2—hindlimb—sarcoma	0.0107	0.0514	CbGeAlD
Bismuth Subsalicylate—PTGS2—cartilage tissue—sarcoma	0.0106	0.0506	CbGeAlD
Bismuth Subsalicylate—TF—hematopoietic system—sarcoma	0.00965	0.0461	CbGeAlD
Bismuth Subsalicylate—TF—connective tissue—sarcoma	0.00929	0.0444	CbGeAlD
Bismuth Subsalicylate—PTGS2—appendage—sarcoma	0.00922	0.0441	CbGeAlD
Bismuth Subsalicylate—Epigastric pain—Mitoxantrone—sarcoma	0.00859	0.0273	CcSEcCtD
Bismuth Subsalicylate—TF—skin of body—sarcoma	0.00839	0.0401	CbGeAlD
Bismuth Subsalicylate—ALB—mammary gland—sarcoma	0.00824	0.0394	CbGeAlD
Bismuth Subsalicylate—TF—uterus—sarcoma	0.00729	0.0349	CbGeAlD
Bismuth Subsalicylate—TF—lymphoid tissue—sarcoma	0.00679	0.0325	CbGeAlD
Bismuth Subsalicylate—TF—bone marrow—sarcoma	0.00618	0.0296	CbGeAlD
Bismuth Subsalicylate—PTGS1—endothelium—sarcoma	0.00582	0.0279	CbGeAlD
Bismuth Subsalicylate—PTGS2—endothelium—sarcoma	0.00557	0.0266	CbGeAlD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—NPM1—sarcoma	0.00557	0.0611	CbGpPWpGaD
Bismuth Subsalicylate—Extravasation—Thiotepa—sarcoma	0.00551	0.0175	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Dactinomycin—sarcoma	0.00547	0.0174	CcSEcCtD
Bismuth Subsalicylate—TF—testis—sarcoma	0.00529	0.0253	CbGeAlD
Bismuth Subsalicylate—Hearing impaired—Thiotepa—sarcoma	0.00505	0.0161	CcSEcCtD
Bismuth Subsalicylate—TF—liver—sarcoma	0.005	0.0239	CbGeAlD
Bismuth Subsalicylate—Extravasation—Vincristine—sarcoma	0.00488	0.0155	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Mitoxantrone—sarcoma	0.00476	0.0151	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Thiotepa—sarcoma	0.00459	0.0146	CcSEcCtD
Bismuth Subsalicylate—TF—Platelet degranulation—VEGFC—sarcoma	0.00446	0.049	CbGpPWpGaD
Bismuth Subsalicylate—Oesophagitis—Thiotepa—sarcoma	0.00439	0.014	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Dactinomycin—sarcoma	0.00436	0.0139	CcSEcCtD
Bismuth Subsalicylate—TF—Response to elevated platelet cytosolic Ca2+—VEGFC—sarcoma	0.00425	0.0467	CbGpPWpGaD
Bismuth Subsalicylate—Phlebitis—Dactinomycin—sarcoma	0.00402	0.0128	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Etoposide—sarcoma	0.00396	0.0126	CcSEcCtD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—CXCR4—sarcoma	0.00393	0.0431	CbGpPWpGaD
Bismuth Subsalicylate—Deafness—Thiotepa—sarcoma	0.0039	0.0124	CcSEcCtD
Bismuth Subsalicylate—TF—lymph node—sarcoma	0.00383	0.0183	CbGeAlD
Bismuth Subsalicylate—Ecchymosis—Mitoxantrone—sarcoma	0.00375	0.0119	CcSEcCtD
Bismuth Subsalicylate—Venous thrombosis—Epirubicin—sarcoma	0.00359	0.0114	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Dactinomycin—sarcoma	0.00353	0.0112	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Mitoxantrone—sarcoma	0.0035	0.0111	CcSEcCtD
Bismuth Subsalicylate—Deafness—Vincristine—sarcoma	0.00346	0.011	CcSEcCtD
Bismuth Subsalicylate—Gastric ulcer—Epirubicin—sarcoma	0.00333	0.0106	CcSEcCtD
Bismuth Subsalicylate—Venous thrombosis—Doxorubicin—sarcoma	0.00332	0.0105	CcSEcCtD
Bismuth Subsalicylate—Skin exfoliation—Etoposide—sarcoma	0.0033	0.0105	CcSEcCtD
Bismuth Subsalicylate—ALB—Scavenging of heme from plasma—HBA1—sarcoma	0.0032	0.0351	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—myometrium—sarcoma	0.00318	0.0152	CbGeAlD
Bismuth Subsalicylate—Oesophagitis—Etoposide—sarcoma	0.00315	0.01	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Vincristine—sarcoma	0.00311	0.00988	CcSEcCtD
Bismuth Subsalicylate—Gastric ulcer—Doxorubicin—sarcoma	0.00308	0.0098	CcSEcCtD
Bismuth Subsalicylate—PTGS2—embryo—sarcoma	0.00306	0.0146	CbGeAlD
Bismuth Subsalicylate—Hyponatraemia—Mitoxantrone—sarcoma	0.00303	0.00962	CcSEcCtD
Bismuth Subsalicylate—PTGS1—seminal vesicle—sarcoma	0.00301	0.0144	CbGeAlD
Bismuth Subsalicylate—Phlebitis—Etoposide—sarcoma	0.00291	0.00925	CcSEcCtD
Bismuth Subsalicylate—PTGS2—seminal vesicle—sarcoma	0.00288	0.0138	CbGeAlD
Bismuth Subsalicylate—PTGS1—hematopoietic system—sarcoma	0.00286	0.0137	CbGeAlD
Bismuth Subsalicylate—TF—Differentiation Pathway—KIT—sarcoma	0.00285	0.0313	CbGpPWpGaD
Bismuth Subsalicylate—Burning sensation—Epirubicin—sarcoma	0.00279	0.00886	CcSEcCtD
Bismuth Subsalicylate—PTGS1—connective tissue—sarcoma	0.00275	0.0132	CbGeAlD
Bismuth Subsalicylate—Abdominal pain upper—Mitoxantrone—sarcoma	0.00275	0.00875	CcSEcCtD
Bismuth Subsalicylate—ALB—testis—sarcoma	0.00275	0.0132	CbGeAlD
Bismuth Subsalicylate—Weight increased—Thiotepa—sarcoma	0.00274	0.00873	CcSEcCtD
Bismuth Subsalicylate—Lung disorder—Epirubicin—sarcoma	0.00273	0.00869	CcSEcCtD
Bismuth Subsalicylate—PTGS2—hematopoietic system—sarcoma	0.00273	0.0131	CbGeAlD
Bismuth Subsalicylate—PTGS2—connective tissue—sarcoma	0.00263	0.0126	CbGeAlD
Bismuth Subsalicylate—ALB—liver—sarcoma	0.0026	0.0124	CbGeAlD
Bismuth Subsalicylate—Burning sensation—Doxorubicin—sarcoma	0.00258	0.0082	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Thiotepa—sarcoma	0.00254	0.00806	CcSEcCtD
Bismuth Subsalicylate—Lung disorder—Doxorubicin—sarcoma	0.00253	0.00804	CcSEcCtD
Bismuth Subsalicylate—PTGS1—smooth muscle tissue—sarcoma	0.00252	0.0121	CbGeAlD
Bismuth Subsalicylate—PTGS2—S1P1 pathway—PLCG1—sarcoma	0.00249	0.0274	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—skin of body—sarcoma	0.00249	0.0119	CbGeAlD
Bismuth Subsalicylate—PTGS2—smooth muscle tissue—sarcoma	0.00241	0.0115	CbGeAlD
Bismuth Subsalicylate—Hallucination—Thiotepa—sarcoma	0.0024	0.00764	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Dactinomycin—sarcoma	0.0024	0.00762	CcSEcCtD
Bismuth Subsalicylate—Stinging—Epirubicin—sarcoma	0.00239	0.0076	CcSEcCtD
Bismuth Subsalicylate—PTGS2—skin of body—sarcoma	0.00238	0.0114	CbGeAlD
Bismuth Subsalicylate—Weight increased—Mitoxantrone—sarcoma	0.00237	0.00754	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Mitoxantrone—sarcoma	0.00232	0.00738	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Dactinomycin—sarcoma	0.00226	0.0072	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Thiotepa—sarcoma	0.00225	0.00716	CcSEcCtD
Bismuth Subsalicylate—Extravasation—Epirubicin—sarcoma	0.00222	0.00705	CcSEcCtD
Bismuth Subsalicylate—Stinging—Doxorubicin—sarcoma	0.00221	0.00703	CcSEcCtD
Bismuth Subsalicylate—PTGS1—cardiac atrium—sarcoma	0.00217	0.0104	CbGeAlD
Bismuth Subsalicylate—PTGS1—uterus—sarcoma	0.00216	0.0103	CbGeAlD
Bismuth Subsalicylate—Hallucination—Vincristine—sarcoma	0.00213	0.00677	CcSEcCtD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—CREB1—sarcoma	0.00211	0.0231	CbGpPWpGaD
Bismuth Subsalicylate—Erythema—Thiotepa—sarcoma	0.0021	0.00668	CcSEcCtD
Bismuth Subsalicylate—Erythema—Dactinomycin—sarcoma	0.00209	0.00663	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Mitoxantrone—sarcoma	0.00208	0.00663	CcSEcCtD
Bismuth Subsalicylate—TF—EPHB forward signaling—SRC—sarcoma	0.00207	0.0227	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—uterus—sarcoma	0.00206	0.00988	CbGeAlD
Bismuth Subsalicylate—Extravasation—Doxorubicin—sarcoma	0.00205	0.00653	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—MITF—sarcoma	0.00201	0.0221	CbGpPWpGaD
Bismuth Subsalicylate—ALB—lymph node—sarcoma	0.00199	0.00954	CbGeAlD
Bismuth Subsalicylate—TF—EPHB forward signaling—NRAS—sarcoma	0.00199	0.0218	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—VEGFC—sarcoma	0.00198	0.0217	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—lymphoid tissue—sarcoma	0.00192	0.00921	CbGeAlD
Bismuth Subsalicylate—PTGS1—tendon—sarcoma	0.00189	0.00906	CbGeAlD
Bismuth Subsalicylate—Skin exfoliation—Epirubicin—sarcoma	0.00185	0.00587	CcSEcCtD
Bismuth Subsalicylate—Erythema—Mitoxantrone—sarcoma	0.00181	0.00577	CcSEcCtD
Bismuth Subsalicylate—PTGS2—tendon—sarcoma	0.00181	0.00866	CbGeAlD
Bismuth Subsalicylate—Dysgeusia—Mitoxantrone—sarcoma	0.00178	0.00565	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Epirubicin—sarcoma	0.00177	0.00562	CcSEcCtD
Bismuth Subsalicylate—PTGS2—S1P1 pathway—PDGFRB—sarcoma	0.00177	0.0194	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—bone marrow—sarcoma	0.00175	0.00838	CbGeAlD
Bismuth Subsalicylate—Ecchymosis—Epirubicin—sarcoma	0.00175	0.00556	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Thiotepa—sarcoma	0.00173	0.0055	CcSEcCtD
Bismuth Subsalicylate—TF—EPHB forward signaling—KRAS—sarcoma	0.00171	0.0188	CbGpPWpGaD
Bismuth Subsalicylate—Skin exfoliation—Doxorubicin—sarcoma	0.00171	0.00544	CcSEcCtD
Bismuth Subsalicylate—TF—Differentiation Pathway—VEGFA—sarcoma	0.00171	0.0187	CbGpPWpGaD
Bismuth Subsalicylate—Infection—Thiotepa—sarcoma	0.0017	0.00542	CcSEcCtD
Bismuth Subsalicylate—Oedema—Dactinomycin—sarcoma	0.0017	0.00541	CcSEcCtD
Bismuth Subsalicylate—Infection—Dactinomycin—sarcoma	0.00169	0.00538	CcSEcCtD
Bismuth Subsalicylate—Erythema multiforme—Etoposide—sarcoma	0.00164	0.00521	CcSEcCtD
Bismuth Subsalicylate—Oesophagitis—Doxorubicin—sarcoma	0.00164	0.0052	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Thiotepa—sarcoma	0.00163	0.0052	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Epirubicin—sarcoma	0.00163	0.00518	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Dactinomycin—sarcoma	0.00162	0.00516	CcSEcCtD
Bismuth Subsalicylate—Ecchymosis—Doxorubicin—sarcoma	0.00162	0.00515	CcSEcCtD
Bismuth Subsalicylate—PTGS1—testis—sarcoma	0.00157	0.0075	CbGeAlD
Bismuth Subsalicylate—Somnolence—Thiotepa—sarcoma	0.00152	0.00485	CcSEcCtD
Bismuth Subsalicylate—Oedema—Vincristine—sarcoma	0.00152	0.00483	CcSEcCtD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—JUN—sarcoma	0.00151	0.0166	CbGpPWpGaD
Bismuth Subsalicylate—Infection—Vincristine—sarcoma	0.00151	0.0048	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Thiotepa—sarcoma	0.00151	0.0048	CcSEcCtD
Bismuth Subsalicylate—Phlebitis—Doxorubicin—sarcoma	0.00151	0.0048	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Mitoxantrone—sarcoma	0.00149	0.00475	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Thiotepa—sarcoma	0.00149	0.00474	CcSEcCtD
Bismuth Subsalicylate—Oedema—Mitoxantrone—sarcoma	0.00148	0.00471	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Dactinomycin—sarcoma	0.00148	0.0047	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Etoposide—sarcoma	0.00148	0.0047	CcSEcCtD
Bismuth Subsalicylate—Infection—Mitoxantrone—sarcoma	0.00147	0.00468	CcSEcCtD
Bismuth Subsalicylate—Constipation—Thiotepa—sarcoma	0.00147	0.00466	CcSEcCtD
Bismuth Subsalicylate—Pain—Thiotepa—sarcoma	0.00147	0.00466	CcSEcCtD
Bismuth Subsalicylate—PTGS2—S1P1 pathway—KDR—sarcoma	0.00146	0.0161	CbGpPWpGaD
Bismuth Subsalicylate—TF—EPHB forward signaling—HRAS—sarcoma	0.00146	0.016	CbGpPWpGaD
Bismuth Subsalicylate—Pain—Dactinomycin—sarcoma	0.00146	0.00463	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—sarcoma	0.00145	0.016	CbGpPWpGaD
Bismuth Subsalicylate—Anorexia—Vincristine—sarcoma	0.00145	0.00461	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Epirubicin—sarcoma	0.00143	0.00456	CcSEcCtD
Bismuth Subsalicylate—PTGS2—liver—sarcoma	0.00142	0.00678	CbGeAlD
Bismuth Subsalicylate—Feeling abnormal—Thiotepa—sarcoma	0.00141	0.00449	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Mitoxantrone—sarcoma	0.00141	0.00449	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Epirubicin—sarcoma	0.00141	0.00448	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Dactinomycin—sarcoma	0.0014	0.00446	CcSEcCtD
Bismuth Subsalicylate—TF—Hemostasis—TEK—sarcoma	0.00139	0.0153	CbGpPWpGaD
Bismuth Subsalicylate—Urticaria—Thiotepa—sarcoma	0.00136	0.00433	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Thiotepa—sarcoma	0.00136	0.00431	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Dactinomycin—sarcoma	0.00135	0.00428	CcSEcCtD
Bismuth Subsalicylate—Lethargy—Doxorubicin—sarcoma	0.00133	0.00422	CcSEcCtD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—VEGFA—sarcoma	0.00132	0.0145	CbGpPWpGaD
Bismuth Subsalicylate—Decreased appetite—Vincristine—sarcoma	0.00132	0.0042	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Mitoxantrone—sarcoma	0.00132	0.00419	CcSEcCtD
Bismuth Subsalicylate—Hyponatraemia—Doxorubicin—sarcoma	0.00131	0.00415	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Mitoxantrone—sarcoma	0.0013	0.00414	CcSEcCtD
Bismuth Subsalicylate—Constipation—Vincristine—sarcoma	0.0013	0.00413	CcSEcCtD
Bismuth Subsalicylate—Pain—Vincristine—sarcoma	0.0013	0.00413	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Mitoxantrone—sarcoma	0.00129	0.00409	CcSEcCtD
Bismuth Subsalicylate—Abdominal pain upper—Epirubicin—sarcoma	0.00128	0.00408	CcSEcCtD
Bismuth Subsalicylate—ALB—Binding and Uptake of Ligands by Scavenger Receptors—HBA1—sarcoma	0.00128	0.014	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—ANGPT2—sarcoma	0.00127	0.014	CbGpPWpGaD
Bismuth Subsalicylate—Pain—Mitoxantrone—sarcoma	0.00127	0.00403	CcSEcCtD
Bismuth Subsalicylate—Constipation—Mitoxantrone—sarcoma	0.00127	0.00403	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Etoposide—sarcoma	0.00124	0.00395	CcSEcCtD
Bismuth Subsalicylate—Infection—Etoposide—sarcoma	0.00122	0.00389	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Mitoxantrone—sarcoma	0.00122	0.00388	CcSEcCtD
Bismuth Subsalicylate—Asthma—Epirubicin—sarcoma	0.00121	0.00386	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Thiotepa—sarcoma	0.00121	0.00386	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Vincristine—sarcoma	0.0012	0.00382	CcSEcCtD
Bismuth Subsalicylate—Abdominal pain upper—Doxorubicin—sarcoma	0.00119	0.00377	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Mitoxantrone—sarcoma	0.00118	0.00374	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Etoposide—sarcoma	0.00117	0.00373	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Thiotepa—sarcoma	0.00117	0.00373	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Mitoxantrone—sarcoma	0.00117	0.00372	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Dactinomycin—sarcoma	0.00116	0.0037	CcSEcCtD
Bismuth Subsalicylate—PTGS1—lymph node—sarcoma	0.00114	0.00543	CbGeAlD
Bismuth Subsalicylate—TF—Platelet degranulation—VEGFA—sarcoma	0.00113	0.0124	CbGpPWpGaD
Bismuth Subsalicylate—Dizziness—Thiotepa—sarcoma	0.00113	0.00361	CcSEcCtD
Bismuth Subsalicylate—Asthma—Doxorubicin—sarcoma	0.00112	0.00357	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Epirubicin—sarcoma	0.0011	0.00351	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Etoposide—sarcoma	0.0011	0.00348	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Thiotepa—sarcoma	0.00109	0.00347	CcSEcCtD
Bismuth Subsalicylate—PTGS2—lymph node—sarcoma	0.00109	0.00519	CbGeAlD
Bismuth Subsalicylate—Drowsiness—Epirubicin—sarcoma	0.00108	0.00344	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Dactinomycin—sarcoma	0.00108	0.00344	CcSEcCtD
Bismuth Subsalicylate—Rash—Thiotepa—sarcoma	0.00108	0.00344	CcSEcCtD
Bismuth Subsalicylate—TF—Response to elevated platelet cytosolic Ca2+—VEGFA—sarcoma	0.00108	0.0119	CbGpPWpGaD
Bismuth Subsalicylate—Dermatitis—Thiotepa—sarcoma	0.00108	0.00343	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—HBA1—sarcoma	0.00108	0.0118	CbGpPWpGaD
Bismuth Subsalicylate—Headache—Thiotepa—sarcoma	0.00107	0.00342	CcSEcCtD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—CD34—sarcoma	0.00107	0.0118	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—MYOD1—sarcoma	0.00107	0.0118	CbGpPWpGaD
Bismuth Subsalicylate—Rash—Dactinomycin—sarcoma	0.00107	0.00341	CcSEcCtD
Bismuth Subsalicylate—ALB—Vitamin B12 Metabolism—HBA1—sarcoma	0.00107	0.0118	CbGpPWpGaD
Bismuth Subsalicylate—Decreased appetite—Etoposide—sarcoma	0.00107	0.0034	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—sarcoma	0.00106	0.0116	CbGpPWpGaD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—CREB1—sarcoma	0.00106	0.0116	CbGpPWpGaD
Bismuth Subsalicylate—Constipation—Etoposide—sarcoma	0.00105	0.00335	CcSEcCtD
Bismuth Subsalicylate—Pain—Etoposide—sarcoma	0.00105	0.00335	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Vincristine—sarcoma	0.00104	0.00331	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Doxorubicin—sarcoma	0.00102	0.00325	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Epirubicin—sarcoma	0.00102	0.00325	CcSEcCtD
Bismuth Subsalicylate—TF—Hemostasis—VEGFC—sarcoma	0.00102	0.0112	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Thiotepa—sarcoma	0.00102	0.00324	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Etoposide—sarcoma	0.00102	0.00323	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Mitoxantrone—sarcoma	0.00101	0.00322	CcSEcCtD
Bismuth Subsalicylate—Nausea—Dactinomycin—sarcoma	0.00101	0.00321	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Vincristine—sarcoma	0.00101	0.0032	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Doxorubicin—sarcoma	0.001	0.00319	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Etoposide—sarcoma	0.000979	0.00311	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Etoposide—sarcoma	0.000974	0.0031	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Epirubicin—sarcoma	0.000972	0.00309	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Vincristine—sarcoma	0.000967	0.00307	CcSEcCtD
Bismuth Subsalicylate—Rash—Vincristine—sarcoma	0.000959	0.00305	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Vincristine—sarcoma	0.000958	0.00305	CcSEcCtD
Bismuth Subsalicylate—Headache—Vincristine—sarcoma	0.000953	0.00303	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Doxorubicin—sarcoma	0.000945	0.003	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Mitoxantrone—sarcoma	0.000942	0.00299	CcSEcCtD
Bismuth Subsalicylate—Rash—Mitoxantrone—sarcoma	0.000934	0.00297	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Mitoxantrone—sarcoma	0.000933	0.00297	CcSEcCtD
Bismuth Subsalicylate—Headache—Mitoxantrone—sarcoma	0.000928	0.00295	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—sarcoma	0.000925	0.0102	CbGpPWpGaD
Bismuth Subsalicylate—Erythema multiforme—Epirubicin—sarcoma	0.000919	0.00292	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Epirubicin—sarcoma	0.000906	0.00288	CcSEcCtD
Bismuth Subsalicylate—Nausea—Vincristine—sarcoma	0.000903	0.00287	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Doxorubicin—sarcoma	0.000899	0.00286	CcSEcCtD
Bismuth Subsalicylate—Nausea—Mitoxantrone—sarcoma	0.00088	0.0028	CcSEcCtD
Bismuth Subsalicylate—ALB—Folate Metabolism—HBA1—sarcoma	0.000873	0.00958	CbGpPWpGaD
Bismuth Subsalicylate—Pruritus—Etoposide—sarcoma	0.000871	0.00277	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—HBA1—sarcoma	0.000857	0.00941	CbGpPWpGaD
Bismuth Subsalicylate—Erythema multiforme—Doxorubicin—sarcoma	0.00085	0.0027	CcSEcCtD
Bismuth Subsalicylate—Erythema—Epirubicin—sarcoma	0.000846	0.00269	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Etoposide—sarcoma	0.000843	0.00268	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Doxorubicin—sarcoma	0.000838	0.00267	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Epirubicin—sarcoma	0.000828	0.00263	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Etoposide—sarcoma	0.000815	0.00259	CcSEcCtD
Bismuth Subsalicylate—ALB—Platelet degranulation—VEGFC—sarcoma	0.000813	0.00892	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—S1P1 pathway—VEGFA—sarcoma	0.000807	0.00885	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—PLCG1—sarcoma	0.000802	0.0088	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—CREB1—sarcoma	0.000787	0.00864	CbGpPWpGaD
Bismuth Subsalicylate—Vomiting—Etoposide—sarcoma	0.000783	0.00249	CcSEcCtD
Bismuth Subsalicylate—Erythema—Doxorubicin—sarcoma	0.000783	0.00249	CcSEcCtD
Bismuth Subsalicylate—Rash—Etoposide—sarcoma	0.000777	0.00247	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Etoposide—sarcoma	0.000776	0.00247	CcSEcCtD
Bismuth Subsalicylate—ALB—Response to elevated platelet cytosolic Ca2+—VEGFC—sarcoma	0.000775	0.0085	CbGpPWpGaD
Bismuth Subsalicylate—Headache—Etoposide—sarcoma	0.000772	0.00245	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Doxorubicin—sarcoma	0.000767	0.00244	CcSEcCtD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—JUN—sarcoma	0.000761	0.00835	CbGpPWpGaD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—CTNNB1—sarcoma	0.000755	0.00829	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Etoposide—sarcoma	0.000732	0.00233	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Epirubicin—sarcoma	0.000696	0.00221	CcSEcCtD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—HBA1—sarcoma	0.000693	0.00761	CbGpPWpGaD
Bismuth Subsalicylate—Oedema—Epirubicin—sarcoma	0.00069	0.0022	CcSEcCtD
Bismuth Subsalicylate—Infection—Epirubicin—sarcoma	0.000686	0.00218	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—sarcoma	0.000677	0.00743	CbGpPWpGaD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—VEGFA—sarcoma	0.000665	0.0073	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—sarcoma	0.000658	0.00722	CbGpPWpGaD
Bismuth Subsalicylate—Anorexia—Epirubicin—sarcoma	0.000658	0.00209	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Doxorubicin—sarcoma	0.000644	0.00205	CcSEcCtD
Bismuth Subsalicylate—Oedema—Doxorubicin—sarcoma	0.000639	0.00203	CcSEcCtD
Bismuth Subsalicylate—Infection—Doxorubicin—sarcoma	0.000635	0.00202	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Epirubicin—sarcoma	0.000614	0.00195	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Doxorubicin—sarcoma	0.000609	0.00194	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Epirubicin—sarcoma	0.000608	0.00193	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Epirubicin—sarcoma	0.0006	0.00191	CcSEcCtD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—IL2—sarcoma	0.000592	0.0065	CbGpPWpGaD
Bismuth Subsalicylate—Constipation—Epirubicin—sarcoma	0.00059	0.00188	CcSEcCtD
Bismuth Subsalicylate—Pain—Epirubicin—sarcoma	0.00059	0.00188	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Epirubicin—sarcoma	0.000569	0.00181	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Doxorubicin—sarcoma	0.000568	0.00181	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—sarcoma	0.000566	0.00622	CbGpPWpGaD
Bismuth Subsalicylate—Dyspepsia—Doxorubicin—sarcoma	0.000562	0.00179	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Doxorubicin—sarcoma	0.000555	0.00177	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Epirubicin—sarcoma	0.000549	0.00174	CcSEcCtD
Bismuth Subsalicylate—Pain—Doxorubicin—sarcoma	0.000546	0.00174	CcSEcCtD
Bismuth Subsalicylate—Constipation—Doxorubicin—sarcoma	0.000546	0.00174	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Epirubicin—sarcoma	0.000546	0.00174	CcSEcCtD
Bismuth Subsalicylate—ALB—FOXA2 and FOXA3 transcription factor networks—CREB1—sarcoma	0.00053	0.00582	CbGpPWpGaD
Bismuth Subsalicylate—Feeling abnormal—Doxorubicin—sarcoma	0.000526	0.00167	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	0.000517	0.00568	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—SRC—sarcoma	0.000516	0.00567	CbGpPWpGaD
Bismuth Subsalicylate—Urticaria—Doxorubicin—sarcoma	0.000508	0.00161	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Doxorubicin—sarcoma	0.000505	0.00161	CcSEcCtD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—VEGFA—sarcoma	0.000503	0.00552	CbGpPWpGaD
Bismuth Subsalicylate—Pruritus—Epirubicin—sarcoma	0.000488	0.00155	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Epirubicin—sarcoma	0.000472	0.0015	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Epirubicin—sarcoma	0.000457	0.00145	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Doxorubicin—sarcoma	0.000452	0.00144	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Epirubicin—sarcoma	0.000439	0.0014	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—sarcoma	0.000438	0.0048	CbGpPWpGaD
Bismuth Subsalicylate—Diarrhoea—Doxorubicin—sarcoma	0.000437	0.00139	CcSEcCtD
Bismuth Subsalicylate—Rash—Epirubicin—sarcoma	0.000435	0.00138	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Epirubicin—sarcoma	0.000435	0.00138	CcSEcCtD
Bismuth Subsalicylate—Headache—Epirubicin—sarcoma	0.000433	0.00138	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—sarcoma	0.000426	0.00467	CbGpPWpGaD
Bismuth Subsalicylate—Dizziness—Doxorubicin—sarcoma	0.000422	0.00134	CcSEcCtD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—KIT—sarcoma	0.000411	0.00451	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Epirubicin—sarcoma	0.00041	0.0013	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—SRC—sarcoma	0.000408	0.00448	CbGpPWpGaD
Bismuth Subsalicylate—Vomiting—Doxorubicin—sarcoma	0.000406	0.00129	CcSEcCtD
Bismuth Subsalicylate—Rash—Doxorubicin—sarcoma	0.000403	0.00128	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Doxorubicin—sarcoma	0.000402	0.00128	CcSEcCtD
Bismuth Subsalicylate—Headache—Doxorubicin—sarcoma	0.0004	0.00127	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—sarcoma	0.000398	0.00436	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—NRAS—sarcoma	0.000393	0.00431	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Doxorubicin—sarcoma	0.000379	0.00121	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—sarcoma	0.000374	0.0041	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—MYC—sarcoma	0.000366	0.00402	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—VEGFC—sarcoma	0.000361	0.00396	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—EGFR—sarcoma	0.000358	0.00393	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—KRAS—sarcoma	0.000338	0.00371	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—IL2—sarcoma	0.000305	0.00335	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—HRAS—sarcoma	0.000287	0.00315	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—IL2—sarcoma	0.000284	0.00311	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—CCND1—sarcoma	0.000282	0.00309	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	0.000275	0.00301	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—SRC—sarcoma	0.000266	0.00292	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—VEGFA—sarcoma	0.000259	0.00285	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—NRAS—sarcoma	0.000256	0.00281	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—TEK—sarcoma	0.000253	0.00278	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—NRAS—sarcoma	0.000243	0.00266	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—ANGPT2—sarcoma	0.000232	0.00254	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—MYC—sarcoma	0.000226	0.00248	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—KRAS—sarcoma	0.00022	0.00242	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—IL2—sarcoma	0.00022	0.00242	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CCND1—sarcoma	0.000215	0.00236	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—KRAS—sarcoma	0.000209	0.00229	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet degranulation—VEGFA—sarcoma	0.000207	0.00227	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	0.000203	0.00222	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—sarcoma	0.000197	0.00216	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—TP53—sarcoma	0.000196	0.00215	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—HRAS—sarcoma	0.000187	0.00206	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—VEGFC—sarcoma	0.000186	0.00204	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—TP53—sarcoma	0.000182	0.002	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—HRAS—sarcoma	0.000177	0.00195	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—MYC—sarcoma	0.000172	0.00189	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—EGFR—sarcoma	0.000168	0.00185	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	0.000168	0.00184	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—PLCG1—sarcoma	0.000146	0.0016	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	0.000146	0.0016	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	0.000146	0.0016	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	0.000145	0.00159	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—TP53—sarcoma	0.000141	0.00155	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—TLE1—sarcoma	0.000132	0.00145	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	0.000131	0.00143	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	0.000127	0.0014	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—NPM1—sarcoma	0.000119	0.00131	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	0.000117	0.00129	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	0.000115	0.00126	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ENO2—sarcoma	0.000109	0.00119	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	0.000108	0.00119	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—HBA1—sarcoma	0.000108	0.00119	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—IL2—sarcoma	0.000108	0.00118	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—ENO2—sarcoma	0.000103	0.00113	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	9.62e-05	0.00106	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—SRC—sarcoma	9.41e-05	0.00103	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PLCG1—sarcoma	9.22e-05	0.00101	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—VEGFA—sarcoma	9.16e-05	0.00101	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PLCG1—sarcoma	8.74e-05	0.00096	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ENO2—sarcoma	8.63e-05	0.000947	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—HBA1—sarcoma	8.57e-05	0.000941	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CXCR4—sarcoma	8.4e-05	0.000922	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—PLCG1—sarcoma	7.32e-05	0.000804	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ENO2—sarcoma	6.98e-05	0.000766	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—HBA1—sarcoma	6.94e-05	0.000761	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—FOXO1—sarcoma	6.2e-05	0.000681	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PDGFRB—sarcoma	6.19e-05	0.00068	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—PDGFRA—sarcoma	6.1e-05	0.000669	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PLCG1—sarcoma	5.92e-05	0.00065	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—IL2—sarcoma	5.56e-05	0.00061	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—SRC—sarcoma	4.85e-05	0.000532	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—KIT—sarcoma	4.73e-05	0.000519	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—VEGFA—sarcoma	4.72e-05	0.000518	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—NRAS—sarcoma	4.67e-05	0.000512	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CREB1—sarcoma	4.5e-05	0.000494	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—KRAS—sarcoma	4.02e-05	0.000441	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MDM2—sarcoma	3.72e-05	0.000409	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—TP53—sarcoma	3.57e-05	0.000392	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—HRAS—sarcoma	3.41e-05	0.000375	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CTNNB1—sarcoma	3.21e-05	0.000352	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—SRC—sarcoma	2.9e-05	0.000319	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—NRAS—sarcoma	2.79e-05	0.000306	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MYC—sarcoma	2.6e-05	0.000285	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—EGFR—sarcoma	2.54e-05	0.000279	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—KRAS—sarcoma	2.4e-05	0.000264	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HRAS—sarcoma	2.04e-05	0.000224	CbGpPWpGaD
